Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSIBOOST: pharmacokinetic boosting of osimertinib with cobicistat in EGFR-mutated NSCLC
NL-OMON55742Active, not recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of osimertinib and cobicistat in non-small cell lung cancer (NSCLC), sponsored by Maastricht University Medical Center+. Primary endpoint: Change in osimertinib exposure (AUC). Started Nov 2020; status: active, not recruiting.
02
Drugs
osimertinibcobicistat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON55742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55742.